# Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

> **NCT07262970** · — · AVAILABLE · sponsor: **Rezolute**

## Conditions studied

- Tumor-associated Hyperinsulinism (Tumor HI)

## Interventions

- **DRUG:** Ersodetug (9 mg/kg) + SOC

## Key facts

- **NCT ID:** NCT07262970
- **Lead sponsor:** Rezolute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07262970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07262970, "Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07262970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*